Pharmaceutical and biotech companies rely on animal research supply chains that involve welfare implications from breeding through experimental use and disposal.
Corporate life science animal welfare responsibility extends beyond in-house research to encompass entire supply chains: breeding facilities, contract research organizations, academic partners, and waste streams. Animals welfare in outsourced research is often less rigorously monitored than in-house work. The 3Rs principle — replace, reduce, refine — is adopted as policy by most major pharmaceutical companies but implementation in supply chains is inconsistent. Effective corporate welfare responsibility requires supplier auditing, welfare KPI reporting, and meaningful reduction targets with accountability mechanisms. Consumer and investor pressure on pharmaceutical companies to demonstrate supply chain welfare accountability is growing.